Loading clinical trials...
Loading clinical trials...
The purpose of this two-part Phase 2 study is to assess the safety, tolerability and efficacy of aerosolized SF-RI 1 (AeroFact) when delivered via nCPAP at two different doses.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Aerogen Pharma Limited
NCT07251790 · Respiratory Distress Syndrome, Newborn, Respiratory Distress Syndrome in Premature Infant
NCT06554522 · Respiratory Distress Syndrome in Premature Infant, RDS of Prematurity, and more
NCT07344714 · Respiratory Distress Syndrome, Newborn, Respiratory Distress Syndrome in Premature Infant, and more
NCT06642285 · Mechanical Ventilation Complication, Respiratory Distress Syndrome in Premature Infant
NCT05609877 · Respiratory Distress Syndrome in Premature Infant
University of Arkansas for Medical Sciences
Little Rock, Arkansas
Alta Bates Summit
Berkeley, California
Children's Hospital Orange County
Orange, California
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions